Literature DB >> 6114900

Complete inhibition of food-stimulated gastric acid secretion by combined application of pirenzepine and ranitidine.

W Londong, V Londong, C Ruthe, P Weizert.   

Abstract

In a double-blind, placebo controlled and randomised secretory study the effectiveness of pirenzepine, ranitidine, and their combination was compared intraindividually in eight healthy subjects receiving intravenous bolus injections. Pirenzepine (0.15 mg/kg) plus ranitidine (0.6 mg/kg) suppressed peptone-stimulated gastric acid secretion from 69 +/- 11 to 2 +/- 0.4 mmol H+/3 h; the mean percentage inhibition was 97%. Postprandial gastrin was unaffected. There were only minor side-effects in a few experiments (reduction of salivation, brief blurring of vision), but no prolactin stimulation after ranitidine or ranitidine plus pirenzepine. The combined application of ranitidine and pirenzepine inhibited meal-stimulated acid secretion more effectively and produced fewer side-effects than the combination of cimetidine plus pirenzepine studied previously.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6114900      PMCID: PMC1419338          DOI: 10.1136/gut.22.7.542

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  25 in total

1.  Optimal effective dose of anticholinergic drug in peptic ulcer therapy.

Authors:  D C SUN; H SHAY
Journal:  AMA Arch Intern Med       Date:  1956-04

2.  Antiulcerogenic effect of a pyrido-benzodiazepine derivative (L-S 519) on experimental ulcers.

Authors:  H Kitagawa; K Kurahashi; M Fujiwara; H Kohei
Journal:  Arzneimittelforschung       Date:  1978

3.  [Progress in diagnosis of gastric function: gastric secretory analysis, intragastric titration, endocrine provocation tests (author's transl)].

Authors:  H D Becker
Journal:  Z Gastroenterol       Date:  1978-03       Impact factor: 2.000

4.  The effect of an H2-receptor antagonist on food-stimulated acid secretion, serum gastrin, and gastric emptying in patients with duodenal ulcers. Comparison with an anticholinergic drug.

Authors:  C T Richardson; B A Bailey; J H Walsh; J S Fordtran
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

5.  Gastric acid secretion rate and buffer content of the stomach after eating. Results in normal subjects and in patients with duodenal ulcer.

Authors:  J S Fordtran; J H Walsh
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

6.  Cimetidine is an antiandrogen in the rat.

Authors:  S J Winters; J L Banks; D L Loriaux
Journal:  Gastroenterology       Date:  1979-03       Impact factor: 22.682

7.  Gynaecomastia associated with cimetidine.

Authors:  R W Spence; L R Celestin
Journal:  Gut       Date:  1979-02       Impact factor: 23.059

8.  [Long-term suppression of H+ secretion through a combination of cimetidine and methanthelinbromide (author's transl)].

Authors:  T Scholten; W P Fritsch; J E Müller; K J Hengels
Journal:  Dtsch Med Wochenschr       Date:  1979-12-28       Impact factor: 0.628

9.  [Inhibition of pentagastrin-stimulated gastric secretion by ranitidine (author's transl)].

Authors:  B Simon; H Kather
Journal:  Dtsch Med Wochenschr       Date:  1979-11-23       Impact factor: 0.628

10.  Gastric response to metiamide.

Authors:  B Thjodleifsson; K G Wormsley
Journal:  Br Med J       Date:  1974-05-11
View more
  8 in total

1.  Pharmacokinetic and pharmacodynamic studies in man simulating acute and chronic treatment with oral pirenzepine.

Authors:  W Londong; V Londong; C Federle; P Tanswell; U Voderholzer
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Effect of cimetidine and pirenzepine in combination on 24 hour intragastric acidity in subjects with previous duodenal ulceration.

Authors:  J G Williams; M Deakin; J K Ramage
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

3.  Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer.

Authors:  H S Merki; L Witzel; D Kaufman; M Kempf; J Neumann; J Röhmel; R P Walt
Journal:  Gut       Date:  1988-04       Impact factor: 23.059

4.  Evaluation of antisecretory drug therapy of Zollinger-Ellison syndrome (ZES) using 24-hour pH monitoring.

Authors:  T Vallot; M Mignon; R Mazure; S Bonfils
Journal:  Dig Dis Sci       Date:  1983-07       Impact factor: 3.199

5.  Combined anti-muscarinic and H2 receptor blockade in the healing of refractory duodenal ulcer. A double blind study.

Authors:  K D Bardhan; M Thompson; K Bose; R F Hinchliffe; J Crowe; D G Weir; C McCarthy; J Walters; T J Thomson; M H Thompson
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

Review 6.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

7.  Telenzepine is at least 25 times more potent than pirenzepine--a dose response and comparative secretory study in man.

Authors:  W Londong; V Londong; A Meierl; U Voderholzer
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

Review 8.  Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.

Authors:  A A Carmine; R N Brogden
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.